Goodwin Advises Repligen in Acquisition of BioLife Solutions for Approximately $1.5 Billion
The Life Sciences and Public M&A teams advised Repligen Corporation (NASDAQ: RGEN) (“Repligen”), a life sciences company focused on bioprocessing technology leadership, in its definitive agreement to acquire BioLife Solutions, Inc., (NASDAQ: BLFS) (“BioLife”) for a total enterprise value of approximately $1.5 billion, comprised of 64% Repligen common stock and 36% cash. The directors of each company unanimously approved the transaction. The transaction is expected to close in the fourth quarter of 2026, subject to customary regulatory approvals, BioLife shareholder approval, and other customary closing conditions.
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is “inspiring advances in bioprocessing” for the customers they serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. The focus areas are filtration and fluid management, chromatography, process analytics, and proteins. Their corporate headquarters are located in Waltham, Massachusetts, and the majority of their manufacturing sites are in the US, with additional key sites in Estonia, Germany, Ireland, the Netherlands, and Sweden.
The Goodwin team was led by Stuart Cable, Jacqueline Mercier, and Tevia Pollard, and included Richie Schwartz, Andrea Akinbola, Keerthi Adusumilli, Bonnee Nie, Hugh Rennie, Haley Carter, Artimus Cunningham, Jeffrey Toomey, John Vernaglia, Julie Tibbets, Elizabeth Mulkey, Matthew Wetzel, Alexandra Denniston, Rahat Tariq, Eric Graffeo, Timothy Holahan, Ana Victoria Alvarado, Daniel Karelitz, Chase Gorland, Scott Bluni, Catherine McCarty, Omer Tene, Aaminah Bhat, Justin Pierce, Kuwabo O’Brien, Mark Tully, Amanda Russo, Adam Bellack, Brian Mukherjee, Amy Koss, Arman Oruc, Paul Jin, Kevin Walsh, Michael Casaburi, and Deborah Birnbach.
For more information, please read the press release.